Publicaciones en colaboración con investigadores/as de Princess Margaret Cancer Centre (17)

2023

  1. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  2. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

2022

  1. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

2021

  1. Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 9

  2. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  3. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

  4. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  5. The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities

    Journal of Thoracic Oncology

2020

  1. Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial

    JAMA Oncology

  2. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 15, Núm. 3, pp. 344-359

2019

  1. An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6709-6720

2016

  1. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477

2014

  1. CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma

    Oncotarget, Vol. 5, Núm. 16, pp. 6854-6866

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

2003

  1. A novel member of the split βαβ fold: Solution structure of the hypothetical protein YML108W from Saccharomyces cerevisiae

    Protein Science, Vol. 12, Núm. 5, pp. 1136-1140

  2. Solution structure of ribosomal protein S28E from Methanobacterium thermoautotrophicum

    Protein Science, Vol. 12, Núm. 12, pp. 2831-2837

2002

  1. NMR structure of the hypothetical protein encoded by the YjbJ gene from Escherichia coli

    Proteins: Structure, Function and Genetics, Vol. 47, Núm. 4, pp. 572-574